Selected Immunological Indicators and Microbiota in Patients With Premature Birth and Preeclampsia
NCT ID: NCT06281262
Last Updated: 2024-03-01
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
100 participants
Study Classification
OBSERVATIONAL
Study Start Date
2023-06-30
Study Completion Date
2025-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal is to demonstrate the relationship of the circulating pool of T-regulatory lymphocytes in the mother's peripheral blood with populations in the placentas and to compare with controls, what is the difference in the expression of individual regulatory molecules of T-regulatory lymphocytes according to new paradigms. The proportional and functional characteristics of T-regulatory lymphocytes will be correlated with the composition of the intestinal and vaginal microbiota.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Different Regulation of Immune Cells in Patients With Preeclampsia
NCT02691364
Preeclampsia
Pregnancy
UNKNOWN
Prediction of Preeclampsia by Comprehensive Markers.
NCT03665623
Pre-Eclampsia
COMPLETED
Maternal Plasmatic Regulatory T Cells and Th17 as Possible Diagnosis Markers of Acute Chorioamnionitis
NCT01610258
Pathology of Pregnancy
COMPLETED
NA
Threatened Preterm Birth and Time of Subsequent Delivery -a Prediction Model
NCT03796949
Preterm Birth
Immunologic Activity Alteration
COMPLETED
Evaluation of the LMWH Thromboprophylaxis in Pregnancy
NCT01394107
Pregnancy
ACTIVE_NOT_RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OBJECTIVES
The primary objective of this project is to determine the differences between the circulating pool of regulatory Treg subpopulation proportions and the placental populations in patients with preterm birth and preeclampsia. Pilot study was conducted for the primary objective. Another objective is to evaluate the effect of microbiota on the regulation of Treg cells, especially in relation to mechanisms of preterm birth and preeclampsia. With growing knowledge of the role of microbiota, it is considered that the maternal microbiota could significantly influence setting of immunoregulatory responses even prenatally. Since Treg play a key role in regulating the immunological balance and are indispensable for induction and maintenance of peripheral tolerance, the investigators hypothesise that abnormalities in function of this population are important factors in increasing the risk of gestational pathologies (preterm birth and preeclampsia). Such dysregulation is most likely accompanied by disruption of the physiological Treg epigenetic profile which is in turn influenced by aberrant microbiota composition. Better understanding of these processes and identification of positively or negatively participating bacterial species could enable more reliable prediction of risk-pregnancy and allow for modulation of microbiota to be applied preventively.
Premature birth is defined as pregnancy termination before the end of the gestational week 37. It plays a role in 10% of all pregnancies including spontaneous or medically induced labours. The efforts to postpone premature labour are continuously developed to minimise the consequences such as low birth weight and other risk events. Preeclampsia is a serious blood pressure condition that develops during pregnancy. People with preeclampsia often have high blood pressure (hypertension) and high levels of protein in their urine (proteinuria). It plays role in 5% of all pregnancies. Preeclampsia typically develops after the 20th week of pregnancy. It can also affect other organs in the body and be dangerous for both the mother and her unborn child. Therefore, a great number of scientific studies are now focused on the early prediction of premature labour and preeclampsia and on finding a specific parameter to estimate female patients at premature labour and preeclampsia risk.
HYPOTHESIS AND AIMS
Hypothesis 1: Disbalance between tolerogenic T cell subsets (Treg, Th2, Th9 and Th22) and proinflammatory subsets (Th1 and Th17) is a sign of premature birth or preeclampsia.
Specific aim 1: Determine the differences between the circulating and the placental T cell subpopulations in patients with preterm birth and preeclampsia. Previously published analyses of Trees and their phenotypic properties give inconclusive or even contradictory results. For this reason, the investigators propose a more in depth approach combining deep immunophenotyping capable of identifying effector T cell, Treg and NK cell subsets and their qualitative phenotype together with assessment of functional capabilities of Tregs.
Hypothesis 2: Certain bacterial species of microbiota can be identified to modulate epigenetic maintenance of Treg phenotype.
Specific aim 2: Determine the influence of microbiota on the Treg regulation. Exposure to microbiota is one of the most important environmental factors introduced in the perinatal period. The capability of certain probiotic bacterial species to promote immunological tolerance, restrain inflammation and unwanted reactivity is being established in the context of intestinal health. Both bacteria and their metabolic products are known to shape the immune system. By influencing the epigenetic programming they modulate phenotype and function of a variety of immune cells including Tregs. The investigators hypothesise that beneficial bacterial species can be identified to promote appropriate epigenetic maintenance of Treg phenotype, function and stability, and thus support Treg tolerogenic role. On the contrary, certain bacterial species will contribute to Treg epigenetic dysregulation and introduce a more pro-inflammatory environment with functionally deficient Treg cells. To test this hypothesis, the investigators will characterise microbial composition of material collected from the mother by oral, rectal and vaginal swabs during pregnancy and at the time of birth.
CHARACTERISATION OF EXPECTED RESULTS
The main outcome of the project will be to improve the understanding of the regulatory processes taking part in the immune balance in preterm birth and preeclampsia. Special attention will be given to the dynamics and functional characteristics of Treg and their subpopulations, considering the role of maternal microbiota. The obtained results will be presented on both national and international congresses and symposia and also published in international impacted journals.
The primary objective of this project is to determine the differences between the circulating pool of regulatory Treg subpopulation proportions and the placental populations in patients with preterm birth and preeclampsia. Pilot study was conducted for the primary objective. Another objective is to evaluate the effect of microbiota on the regulation of Treg cells, especially in relation to mechanisms of preterm birth and preeclampsia. With growing knowledge of the role of microbiota, it is considered that the maternal microbiota could significantly influence setting of immunoregulatory responses even prenatally. Since Treg play a key role in regulating the immunological balance and are indispensable for induction and maintenance of peripheral tolerance, the investigators hypothesise that abnormalities in function of this population are important factors in increasing the risk of gestational pathologies (preterm birth and preeclampsia). Such dysregulation is most likely accompanied by disruption of the physiological Treg epigenetic profile which is in turn influenced by aberrant microbiota composition. Better understanding of these processes and identification of positively or negatively participating bacterial species could enable more reliable prediction of risk-pregnancy and allow for modulation of microbiota to be applied preventively.
Premature birth is defined as pregnancy termination before the end of the gestational week 37. It plays a role in 10% of all pregnancies including spontaneous or medically induced labours. The efforts to postpone premature labour are continuously developed to minimise the consequences such as low birth weight and other risk events. Preeclampsia is a serious blood pressure condition that develops during pregnancy. People with preeclampsia often have high blood pressure (hypertension) and high levels of protein in their urine (proteinuria). It plays role in 5% of all pregnancies. Preeclampsia typically develops after the 20th week of pregnancy. It can also affect other organs in the body and be dangerous for both the mother and her unborn child. Therefore, a great number of scientific studies are now focused on the early prediction of premature labour and preeclampsia and on finding a specific parameter to estimate female patients at premature labour and preeclampsia risk.
HYPOTHESIS AND AIMS
Hypothesis 1: Disbalance between tolerogenic T cell subsets (Treg, Th2, Th9 and Th22) and proinflammatory subsets (Th1 and Th17) is a sign of premature birth or preeclampsia.
Specific aim 1: Determine the differences between the circulating and the placental T cell subpopulations in patients with preterm birth and preeclampsia. Previously published analyses of Trees and their phenotypic properties give inconclusive or even contradictory results. For this reason, the investigators propose a more in depth approach combining deep immunophenotyping capable of identifying effector T cell, Treg and NK cell subsets and their qualitative phenotype together with assessment of functional capabilities of Tregs.
Hypothesis 2: Certain bacterial species of microbiota can be identified to modulate epigenetic maintenance of Treg phenotype.
Specific aim 2: Determine the influence of microbiota on the Treg regulation. Exposure to microbiota is one of the most important environmental factors introduced in the perinatal period. The capability of certain probiotic bacterial species to promote immunological tolerance, restrain inflammation and unwanted reactivity is being established in the context of intestinal health. Both bacteria and their metabolic products are known to shape the immune system. By influencing the epigenetic programming they modulate phenotype and function of a variety of immune cells including Tregs. The investigators hypothesise that beneficial bacterial species can be identified to promote appropriate epigenetic maintenance of Treg phenotype, function and stability, and thus support Treg tolerogenic role. On the contrary, certain bacterial species will contribute to Treg epigenetic dysregulation and introduce a more pro-inflammatory environment with functionally deficient Treg cells. To test this hypothesis, the investigators will characterise microbial composition of material collected from the mother by oral, rectal and vaginal swabs during pregnancy and at the time of birth.
CHARACTERISATION OF EXPECTED RESULTS
The main outcome of the project will be to improve the understanding of the regulatory processes taking part in the immune balance in preterm birth and preeclampsia. Special attention will be given to the dynamics and functional characteristics of Treg and their subpopulations, considering the role of maternal microbiota. The obtained results will be presented on both national and international congresses and symposia and also published in international impacted journals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Preterm Birth
Preeclampsia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pregnant women
Singletone pregnancy, gestational age 9+0 - 12+0, history of preeclampsia (PE) or spontaneous preterm birth (PTL = preterm labour) or pPROM (preterm premature rupture of membranes).
Peripheral blood collection
Intervention Type
DIAGNOSTIC_TEST
The phenotypic characteristics of leukocytes will be compared between the groups to identify immunological markers of women at risk of preterm delivery.
Samples from the controls will be taken to define a baseline for the measured leukocyte populations.
Swab sample collection
Intervention Type
DIAGNOSTIC_TEST
Oral, vaginal and rectal swabs will be collected and stored for analysis of microbiota at the time of inclusion. At birth, oral, vaginal and rectal swabs and part of the placenta (placental tissue) will be collected for further analysis.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Peripheral blood collection
The phenotypic characteristics of leukocytes will be compared between the groups to identify immunological markers of women at risk of preterm delivery.
Samples from the controls will be taken to define a baseline for the measured leukocyte populations.
Intervention Type
DIAGNOSTIC_TEST
Swab sample collection
Oral, vaginal and rectal swabs will be collected and stored for analysis of microbiota at the time of inclusion. At birth, oral, vaginal and rectal swabs and part of the placenta (placental tissue) will be collected for further analysis.
Intervention Type
DIAGNOSTIC_TEST
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* singletone pregnancy
* gestational age 9+0 - 12+0
* history of preeclampsia (PE)
* history of spontaneous preterm birth (PTL = preterm labour)
* history of pPROM (preterm premature rupture of membranes).
* gestational age 9+0 - 12+0
* history of preeclampsia (PE)
* history of spontaneous preterm birth (PTL = preterm labour)
* history of pPROM (preterm premature rupture of membranes).
Exclusion Criteria
* uterine malformations
* gestational age out of 9+0 - 12+0
* age out of 19-40
* gestational age out of 9+0 - 12+0
* age out of 19-40
Minimum Eligible Age
19 Years
Maximum Eligible Age
40 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Charles University, Czech Republic
OTHER
Sponsor Role
collaborator
Institute of Hematology and Blood Transfusion, Czech Republic
OTHER
Sponsor Role
collaborator
General University Hospital, Prague
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zdenek Lastuvka
Principal investigator, MD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zdeněk Laštůvka, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
General University Hospital, Prague
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Gynaecology, Obstetrics and Neonatology of the First Faculty of Medicine of the Charles University and General University Hospital in Prague
Prague, , Czechia
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Czechia
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Perin J, Mulick A, Yeung D, Villavicencio F, Lopez G, Strong KL, Prieto-Merino D, Cousens S, Black RE, Liu L. Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet Child Adolesc Health. 2022 Feb;6(2):106-115. doi: 10.1016/S2352-4642(21)00311-4. Epub 2021 Nov 17.
Reference Type
BACKGROUND
Ohuma EO, Moller AB, Bradley E, Chakwera S, Hussain-Alkhateeb L, Lewin A, Okwaraji YB, Mahanani WR, Johansson EW, Lavin T, Fernandez DE, Dominguez GG, de Costa A, Cresswell JA, Krasevec J, Lawn JE, Blencowe H, Requejo J, Moran AC. National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis. Lancet. 2023 Oct 7;402(10409):1261-1271. doi: 10.1016/S0140-6736(23)00878-4.
Reference Type
BACKGROUND
Manuck TA. Racial and ethnic differences in preterm birth: A complex, multifactorial problem. Semin Perinatol. 2017 Dec;41(8):511-518. doi: 10.1053/j.semperi.2017.08.010. Epub 2017 Sep 21.
Reference Type
BACKGROUND
Chawanpaiboon S, Vogel JP, Moller AB, Lumbiganon P, Petzold M, Hogan D, Landoulsi S, Jampathong N, Kongwattanakul K, Laopaiboon M, Lewis C, Rattanakanokchai S, Teng DN, Thinkhamrop J, Watananirun K, Zhang J, Zhou W, Gulmezoglu AM. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob Health. 2019 Jan;7(1):e37-e46. doi: 10.1016/S2214-109X(18)30451-0. Epub 2018 Oct 30.
Reference Type
BACKGROUND
Ream MA, Lehwald L. Neurologic Consequences of Preterm Birth. Curr Neurol Neurosci Rep. 2018 Jun 16;18(8):48. doi: 10.1007/s11910-018-0862-2.
Reference Type
BACKGROUND
Green ES, Arck PC. Pathogenesis of preterm birth: bidirectional inflammation in mother and fetus. Semin Immunopathol. 2020 Aug;42(4):413-429. doi: 10.1007/s00281-020-00807-y. Epub 2020 Sep 7.
Reference Type
BACKGROUND
Gomez-Lopez N, Arenas-Hernandez M, Romero R, Miller D, Garcia-Flores V, Leng Y, Xu Y, Galaz J, Hassan SS, Hsu CD, Tse H, Sanchez-Torres C, Done B, Tarca AL. Regulatory T Cells Play a Role in a Subset of Idiopathic Preterm Labor/Birth and Adverse Neonatal Outcomes. Cell Rep. 2020 Jul 7;32(1):107874. doi: 10.1016/j.celrep.2020.107874.
Reference Type
BACKGROUND
Robertson SA, Care AS, Moldenhauer LM. Regulatory T cells in embryo implantation and the immune response to pregnancy. J Clin Invest. 2018 Oct 1;128(10):4224-4235. doi: 10.1172/JCI122182. Epub 2018 Oct 1.
Reference Type
BACKGROUND
Xue L, Gyles SL, Wettey FR, Gazi L, Townsend E, Hunter MG, Pettipher R. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol. 2005 Nov 15;175(10):6531-6. doi: 10.4049/jimmunol.175.10.6531.
Reference Type
BACKGROUND
Tsuda S, Zhang X, Hamana H, Shima T, Ushijima A, Tsuda K, Muraguchi A, Kishi H, Saito S. Clonally Expanded Decidual Effector Regulatory T Cells Increase in Late Gestation of Normal Pregnancy, but Not in Preeclampsia, in Humans. Front Immunol. 2018 Aug 24;9:1934. doi: 10.3389/fimmu.2018.01934. eCollection 2018.
Reference Type
BACKGROUND
Rowe JH, Ertelt JM, Xin L, Way SS. Pregnancy imprints regulatory memory that sustains anergy to fetal antigen. Nature. 2012 Oct 4;490(7418):102-6. doi: 10.1038/nature11462. Epub 2012 Sep 26.
Reference Type
BACKGROUND
Schober L, Radnai D, Schmitt E, Mahnke K, Sohn C, Steinborn A. Term and preterm labor: decreased suppressive activity and changes in composition of the regulatory T-cell pool. Immunol Cell Biol. 2012 Nov;90(10):935-44. doi: 10.1038/icb.2012.33. Epub 2012 Jul 3.
Reference Type
BACKGROUND
Tilburgs T, Roelen DL, van der Mast BJ, de Groot-Swings GM, Kleijburg C, Scherjon SA, Claas FH. Evidence for a selective migration of fetus-specific CD4+CD25bright regulatory T cells from the peripheral blood to the decidua in human pregnancy. J Immunol. 2008 Apr 15;180(8):5737-45. doi: 10.4049/jimmunol.180.8.5737.
Reference Type
BACKGROUND
Krop J, Heidt S, Claas FHJ, Eikmans M. Regulatory T Cells in Pregnancy: It Is Not All About FoxP3. Front Immunol. 2020 Jun 23;11:1182. doi: 10.3389/fimmu.2020.01182. eCollection 2020.
Reference Type
BACKGROUND
Green S, Politis M, Rallis KS, Saenz de Villaverde Cortabarria A, Efthymiou A, Mureanu N, Dalrymple KV, Scotta C, Lombardi G, Tribe RM, Nicolaides KH, Shangaris P. Regulatory T Cells in Pregnancy Adverse Outcomes: A Systematic Review and Meta-Analysis. Front Immunol. 2021 Oct 29;12:737862. doi: 10.3389/fimmu.2021.737862. eCollection 2021.
Reference Type
BACKGROUND
Tsuda S, Nakashima A, Shima T, Saito S. New Paradigm in the Role of Regulatory T Cells During Pregnancy. Front Immunol. 2019 Mar 26;10:573. doi: 10.3389/fimmu.2019.00573. eCollection 2019.
Reference Type
BACKGROUND
Rudensky AY. Regulatory T cells and Foxp3. Immunol Rev. 2011 May;241(1):260-8. doi: 10.1111/j.1600-065X.2011.01018.x.
Reference Type
BACKGROUND
Yadav M, Stephan S, Bluestone JA. Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front Immunol. 2013 Aug 7;4:232. doi: 10.3389/fimmu.2013.00232. eCollection 2013.
Reference Type
BACKGROUND
Elkord E. Helios Should Not Be Cited as a Marker of Human Thymus-Derived Tregs. Commentary: Helios(+) and Helios(-) Cells Coexist within the Natural FOXP3(+) T Regulatory Cell Subset in Humans. Front Immunol. 2016 Jul 8;7:276. doi: 10.3389/fimmu.2016.00276. eCollection 2016. No abstract available.
Reference Type
BACKGROUND
Kim HJ, Barnitz RA, Kreslavsky T, Brown FD, Moffett H, Lemieux ME, Kaygusuz Y, Meissner T, Holderried TA, Chan S, Kastner P, Haining WN, Cantor H. Stable inhibitory activity of regulatory T cells requires the transcription factor Helios. Science. 2015 Oct 16;350(6258):334-9. doi: 10.1126/science.aad0616.
Reference Type
BACKGROUND
Yu WQ, Ji NF, Gu CJ, Wang YL, Huang M, Zhang MS. Coexpression of Helios in Foxp3+ Regulatory T Cells and Its Role in Human Disease. Dis Markers. 2021 Jun 22;2021:5574472. doi: 10.1155/2021/5574472. eCollection 2021.
Reference Type
BACKGROUND
Shevyrev D, Tereshchenko V. Treg Heterogeneity, Function, and Homeostasis. Front Immunol. 2020 Jan 14;10:3100. doi: 10.3389/fimmu.2019.03100. eCollection 2019.
Reference Type
BACKGROUND
Zhao H, Bo C, Kang Y, Li H. What Else Can CD39 Tell Us? Front Immunol. 2017 Jun 22;8:727. doi: 10.3389/fimmu.2017.00727. eCollection 2017.
Reference Type
BACKGROUND
Svensson-Arvelund J, Mehta RB, Lindau R, Mirrasekhian E, Rodriguez-Martinez H, Berg G, Lash GE, Jenmalm MC, Ernerudh J. The human fetal placenta promotes tolerance against the semiallogeneic fetus by inducing regulatory T cells and homeostatic M2 macrophages. J Immunol. 2015 Feb 15;194(4):1534-44. doi: 10.4049/jimmunol.1401536. Epub 2015 Jan 5.
Reference Type
BACKGROUND
Wang S, Zhu X, Xu Y, Zhang D, Li Y, Tao Y, Piao H, Li D, Du M. Programmed cell death-1 (PD-1) and T-cell immunoglobulin mucin-3 (Tim-3) regulate CD4+ T cells to induce Type 2 helper T cell (Th2) bias at the maternal-fetal interface. Hum Reprod. 2016 Apr;31(4):700-11. doi: 10.1093/humrep/dew019. Epub 2016 Feb 16.
Reference Type
BACKGROUND
Wang W, Sung N, Gilman-Sachs A, Kwak-Kim J. T Helper (Th) Cell Profiles in Pregnancy and Recurrent Pregnancy Losses: Th1/Th2/Th9/Th17/Th22/Tfh Cells. Front Immunol. 2020 Aug 18;11:2025. doi: 10.3389/fimmu.2020.02025. eCollection 2020.
Reference Type
BACKGROUND
Travis OK, White D, Pierce WA, Ge Y, Stubbs CY, Spradley FT, Williams JM, Cornelius DC. Chronic infusion of interleukin-17 promotes hypertension, activation of cytolytic natural killer cells, and vascular dysfunction in pregnant rats. Physiol Rep. 2019 Apr;7(7):e14038. doi: 10.14814/phy2.14038.
Reference Type
BACKGROUND
Wang WJ, Hao CF, Yi-Lin, Yin GJ, Bao SH, Qiu LH, Lin QD. Increased prevalence of T helper 17 (Th17) cells in peripheral blood and decidua in unexplained recurrent spontaneous abortion patients. J Reprod Immunol. 2010 Mar;84(2):164-70. doi: 10.1016/j.jri.2009.12.003. Epub 2010 Jan 27.
Reference Type
BACKGROUND
van der Zwan A, Bi K, Norwitz ER, Crespo AC, Claas FHJ, Strominger JL, Tilburgs T. Mixed signature of activation and dysfunction allows human decidual CD8+ T cells to provide both tolerance and immunity. Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):385-390. doi: 10.1073/pnas.1713957115. Epub 2017 Dec 19.
Reference Type
BACKGROUND
Jabrane-Ferrat N. Features of Human Decidual NK Cells in Healthy Pregnancy and During Viral Infection. Front Immunol. 2019 Jun 28;10:1397. doi: 10.3389/fimmu.2019.01397. eCollection 2019.
Reference Type
BACKGROUND
Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol. 2002 Sep;2(9):656-63. doi: 10.1038/nri886.
Reference Type
BACKGROUND
Thomsen SF. Epidemiology and natural history of atopic diseases. Eur Clin Respir J. 2015 Mar 24;2. doi: 10.3402/ecrj.v2.24642. eCollection 2015.
Reference Type
BACKGROUND
Hagihara Y, Yoshimatsu Y, Mikami Y, Takada Y, Mizuno S, Kanai T. Epigenetic regulation of T helper cells and intestinal pathogenicity. Semin Immunopathol. 2019 May;41(3):379-399. doi: 10.1007/s00281-019-00732-9. Epub 2019 Mar 19.
Reference Type
BACKGROUND
Berni Canani R, Paparo L, Nocerino R, Di Scala C, Della Gatta G, Maddalena Y, Buono A, Bruno C, Voto L, Ercolini D. Gut Microbiome as Target for Innovative Strategies Against Food Allergy. Front Immunol. 2019 Feb 15;10:191. doi: 10.3389/fimmu.2019.00191. eCollection 2019.
Reference Type
BACKGROUND
Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007 May;39(2):175-91. doi: 10.3758/bf03193146.
Reference Type
BACKGROUND
Nakashima A, Ito M, Shima T, Bac ND, Hidaka T, Saito S. Accumulation of IL-17-positive cells in decidua of inevitable abortion cases. Am J Reprod Immunol. 2010 Jul 1;64(1):4-11. doi: 10.1111/j.1600-0897.2010.00812.x. Epub 2010 Mar 4.
Reference Type
BACKGROUND
Vanikova S, Koladiya A, Musil J. OMIP-080: 29-Color flow cytometry panel for comprehensive evaluation of NK and T cells reconstitution after hematopoietic stem cells transplantation. Cytometry A. 2022 Jan;101(1):21-26. doi: 10.1002/cyto.a.24510. Epub 2021 Oct 24.
Reference Type
BACKGROUND
Kratochvil M, Koladiya A, Vondrasek J. Generalized EmbedSOM on quadtree-structured self-organizing maps. F1000Res. 2019 Dec 18;8:2120. doi: 10.12688/f1000research.21642.2. eCollection 2019.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GIP-23-L-04-223
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Molecular Study of the Maternal-fetal Interface in Preeclampsia.
NCT06232668
RECRUITING
Role of the Maternal Microbiota on the Immune Response and Metabolism During Hypertensive Disorders
NCT06421493
RECRUITING
Labor Characteristics and Outcomes in Women With Gestational Hypertension or Preeclampsia Who Underwent Labor Induction
NCT06907576
COMPLETED
Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Retardation: A Longtitudinal Study
NCT00340899
COMPLETED
Immunomodulation During Pregnancy
NCT06882850
RECRUITING
Mechanisms of Maternal Immune Tolerance in Early Pregnancy
NCT07297394
NOT_YET_RECRUITING
Prediction and Prevention of Preterm Birth (PREVENT-PTB Study)
NCT03530332
TERMINATED
NA
Evaluating Pathophysiological Mechanisms of Acute and Chronic Heat Stress on Maternal and Fetal Health
NCT07326176
COMPLETED
NA
Study of the Physiology of Pre-eclampsia and Vascular IUGR With Constitution of a Biological Collection
NCT03626233
UNKNOWN
Cardiac and Immune Cell Function in Preeclampsia
NCT04508582
COMPLETED
Protein and Ultrasound Indicators of Preterm Birth
NCT01412931
COMPLETED
Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers
NCT02808494
COMPLETED
Agouti-related Peptide (AgRP) in Healthy Mothers and Mothers With Preeclampsia and Their Offspring
NCT01042210
COMPLETED
Analyses of Interleukin-6, Presepsin and Pentraxin-3 in the Diagnosis and Severity of Late-onset Preeclampsia
NCT04126902
COMPLETED
The Combined First Trimester Screening
NCT07015203
NOT_YET_RECRUITING
Regulation Of Maternal Fuel Supply And Neonatal Adiposity
NCT00826904
COMPLETED
GenerationGemelli: Longitudinal Study for the Evaluation of the Maternal Exposome on the Health of the Newborn and Child
NCT06617650
RECRUITING
Berlin-Brandenburg Pregnancy Cohort
NCT03313024
RECRUITING
Role of Anti-C1q Autoantibodies in Pregnancy
NCT06317467
RECRUITING
Routine Fetal RhD Genotyping for RhD- Pregnant Women
NCT00832962
COMPLETED
Pregnancy-Related Hypertension: Adherence to a New Type of Monitoring
NCT04823949
COMPLETED
NA
Preterm Birth and Biomarkers for Cardiovascular Disease
NCT05693285
COMPLETED
IMPACT OF THE BIOLOGICAL RATIO ON MEDICAL DECISION MAKING IN WOMEN SUSPECTED OF PREECLAMPSIA
NCT06224946
COMPLETED
Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19
NCT04718220
COMPLETED
NA
Peripartum Anesthetic Management of Patients With Preeclampsia
NCT05237011
UNKNOWN